Oxford Biomedica Solutions
Mayo Brown is an experienced professional in the field of regulatory science and quality assurance, currently serving as Associate Director of Regulatory Science - CMC at Oxford Biomedica since March 2022. Responsibilities include developing global regulatory CMC strategies, leading high-quality regulatory submissions for gene therapy products, and assessing changes for post-approval modifications. Previously, Mayo held the role of Sr. Manager of Regulatory Science - CMC at Homology Medicines, where oversight of external manufacturing and quality operations was a key focus. Additional experience includes positions as Manufacturing Specialist at bluebird bio and Sanofi Genzyme, contributing to various aspects of manufacturing operations, technology transfer, and compliance. Educationally, Mayo holds a Bachelor's degree in Chemical Engineering from Villanova University.
This person is not in any teams
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.